2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

Gavi's new CEO must prioritise catch-up vaccinations for young children, and more inclusive decision-making.

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

A MSF report released today finds that two newer TB drugs – bedaquiline and delamanid – going off patent in 2023 presents a critical opportunity to increase access to shorter, safer and better treatment for people with drug-resistant ...

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

MSF reiterates that the price of a full DR-TB treatment course should be no more than US$500 per person.

Due to the high number of countries currently experiencing cholera outbreaks and a shortage of oral cholera vaccine, the International Coordinating Group (ICG) announced today that it will temporarily suspend the standard two-dose ...

On 5 October 2022, the World Health Organization (WHO) announced that South Africa’s vaccine regulatory system reached functional maturity (maturity level three [ML3]), recognising “that South Africa has a well-functioning and ...

Delays in supply of the critical GeneXpert TB test are unacceptable. Now more than ever, we need a doubling down on urgent actions to help countries scale up lifesaving TB testing.

MSF calls for full production capability in Aspen and Serum Institute of India fill and finish agreement for four vaccines

At 2022 International AIDS Conference, MSF calls for increased access to long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP).

MSF reiterates call for BioNTech to urgently transfer mRNA vaccine technology to WHO mRNA technology transfer hub in South Africa as well as manufacturers in low- and middle-income countries, as faster option.

MSF reiterates its commitment to diagnosing and treating life-threatening NTDs in humanitarian settings as it signs the Kigali Declaration

MSF is disappointed in the inadequate outcome after nearly two years of discussions at the WTO  

The People's Vaccine Alliance, Oxfam, Section27 of South Africa, MSF, and more than 150 CSOs called on Trade Ministers at the WTO not to accept the current draft of the Ministerial Decision on the TRIPS Agreement and demand a real ...

Governments negotiating at the WTO must stand strong against problematic draft decision text at ministerial conference and work to agree on a real Waiver

To effectively increase people’s access to all COVID medical tools, governments must return to TRIPS Waiver proposed over 20 months ago

On the eve of BioNTech’s annual shareholder meeting, where the German pharmaceutical corporation is expected to report billions of euros in profits from COVID vaccine sales, MSF urged the German government, which supported BioNTech’s ...